AstraZeneca (AZN) News Today £124.87 -66.76 (-0.53%) As of 10/17/2025 12:28 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock AZN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period AstraZeneca cut to Sell by Deutsche Bank on pipeline doubts, patent riskOctober 16 at 8:10 AM | uk.investing.comAstraZeneca downgraded to Sell from Hold at Deutsche BankOctober 16 at 8:10 AM | msn.comAstraZeneca (LON:AZN) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?October 15 at 4:41 AM | marketbeat.comAstraZeneca (LON:AZN) Earns "Overweight" Rating from JPMorgan Chase & Co.October 15 at 2:08 AM | americanbankingnews.comUBS Keeps Their Buy Rating on AstraZeneca (AZN)October 14, 2025 | theglobeandmail.comJP Morgan Cazenove Reiterates AstraZeneca PLC - Depositary Receipt (AZN) Overweight RecommendationOctober 14, 2025 | msn.comAstraZeneca confirms deal with U.S. to lower cost of medicinesOctober 13, 2025 | msn.comAstraZeneca (LON:AZN) Receives "Overweight" Rating from JPMorgan Chase & Co.October 13, 2025 | marketbeat.comAstraZeneca Joins US President Trump's Drug-Cost Initiative, Secures Tariff ReprieveOctober 13, 2025 | uk.finance.yahoo.comAstrazeneca CEO's bizarre expression at Trump's presser viral; ‘trying to control’ - WatchOctober 10, 2025 | msn.comAstraZeneca's (AZN) "Buy" Rating Reiterated at Shore CapitalOctober 10, 2025 | americanbankingnews.comAstraZeneca eyes $500M additional investment in new Virginia plantOctober 9, 2025 | msn.comAstraZeneca Announces $4.5B Investment In VirginiaOctober 9, 2025 | msn.comAstraZeneca (LON:AZN) Given "Buy" Rating at Shore CapitalOctober 7, 2025 | marketbeat.comAstraZeneca (LON:AZN) Reaches New 12-Month High - Here's WhyOctober 7, 2025 | marketbeat.comAstraZeneca reports improvement in dual primary endpoint of Datroway studyOctober 6, 2025 | msn.comAstraZeneca (LON:AZN) Share Price Passes Above 200 Day Moving Average - Time to Sell?October 3, 2025 | marketbeat.comAstraZeneca (AZN) Jumps to All-Time High on Trump Drug Tariff DelayOctober 2, 2025 | insidermonkey.comAstraZeneca (LON:AZN) Sets New 52-Week High - Should You Buy?October 1, 2025 | marketbeat.comAstraZeneca, Daiichi win FDA review for Enhertu label expansionOctober 1, 2025 | msn.comAstraZeneca to pursue direct listing in the US while maintaining UK listingSeptember 29, 2025 | msn.comAstraZeneca’s game of exit chess puts UK in checkSeptember 29, 2025 | reuters.comAstraZeneca announces plan to harmonize share listing across major exchangesSeptember 29, 2025 | investing.comAstraZeneca to directly list shares in New York, retain UK listingSeptember 29, 2025 | reuters.comAmgen Inc.’s (AMGN) and AstraZeneca’s (AZN) Tezspire Receives Positive Recommendation from the EU Medicines AgencySeptember 29, 2025 | msn.comAstraZeneca (LON:AZN) Stock Price Passes Above Two Hundred Day Moving Average - Time to Sell?September 25, 2025 | marketbeat.comAstraZeneca, Amgen’s Tezspire recommended for approval in EUSeptember 22, 2025 | msn.comAstraZeneca (LSE:AZN): Exploring Current Valuation Signals and Analyst NarrativesSeptember 20, 2025 | finance.yahoo.comJ.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)September 19, 2025 | theglobeandmail.comAstraZeneca (LON:AZN) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?September 18, 2025 | marketbeat.comAstraZeneca Says Asthma Drug Failed Trial In Smoker’s DiseaseSeptember 17, 2025 | msn.comAstraZeneca fails to meet main goal in lung disease trialSeptember 17, 2025 | msn.comAstraZeneca posts late-stage trial win for injectable Saphnelo in SLESeptember 17, 2025 | msn.comAstraZeneca falls 3% as £200m Cambridge expansion put on holdSeptember 15, 2025 | uk.investing.comAstraZeneca PLC (AZN) Receives Tagrisso Boost in Lung Cancer TrialsSeptember 15, 2025 | msn.comENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid TumorsSeptember 11, 2025 | finance.yahoo.comAstraZeneca (LON:AZN) Share Price Passes Above Two Hundred Day Moving Average - Here's What HappenedSeptember 10, 2025 | marketbeat.comAstraZeneca’s Tezepelumab Study: A Potential Game-Changer for COPD TreatmentSeptember 8, 2025 | msn.comGoldman Sachs Remains Bullish on AstraZeneca (AZN)September 6, 2025 | msn.comAstraZeneca, Corning And More On CNBC's 'Final Trades'September 4, 2025 | benzinga.comJust over £119 now, AstraZeneca’s share price looks cheap to me anywhere under £220.91September 3, 2025 | uk.finance.yahoo.comAstraZeneca (LON:AZN) Given Buy Rating at Berenberg BankSeptember 3, 2025 | marketbeat.comWhy Mineralys Nearly Doubled On AstraZeneca's Hypertension ResultsSeptember 3, 2025 | msn.comMerck's cholesterol drug gets a boost with another late-stage trial successSeptember 2, 2025 | msn.comAstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood PressureSeptember 2, 2025 | finance.yahoo.comAfter this weekend’s news, is it time to look again at the AstraZeneca share price?September 1, 2025 | uk.finance.yahoo.comDeutsche Bank Sticks to Their Hold Rating for AstraZeneca (AZN)August 28, 2025 | theglobeandmail.comAstraZeneca PLC (AZN) Oncology Sales Hit $12B in H1 2025August 28, 2025 | insidermonkey.comAstraZeneca (LON:AZN) Stock Price Crosses Above 200-Day Moving Average - What's Next?August 25, 2025 | marketbeat.comSweden's Wallenberg groups launch joint AI companyAugust 22, 2025 | msn.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZN Media Mentions By Week AZN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZN News Sentiment▼-0.030.46▲Average Medical News Sentiment AZN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZN Articles This Week▼115▲AZN Articles Average Week Get the Latest News and Ratings for AZN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies GSK News Ithaca Energy News HUTCHMED News Indivior News Grainger News Bloomsbury Publishing News India Capital Growth News Alpha Real Trust News Aura Energy News Pharos Energy News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:AZN) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
